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(http://creativecommons.org/licenses/by-nc-nd/4.0/).The most widely used immunoassay conﬁguration is the enzyme-linked immunosorbent assay (ELISA)
because the procedure produces highly sensitive and speciﬁc results and generally is easy to use. By
deﬁnition, ELISAs are immunoassays used to detect a substance (typically an antigen or antibody) in which
an enzyme is attached (conjugated) to one of the reactants and an enzymatic reaction is used to amplify
the signal if the substance is present. Optimized ELISAs include several steps that are performed in
sequence using a deﬁned protocol that typically includes application of sample and an enzyme-conjugated
antibody or antigen to an immobilized reagent, followed by wash and enzyme reaction steps. The SNAP
assay is an in-clinic device that performs each of the ELISA steps in a timed sequential fashion with little
consumer interface. The components and mechanical mechanism of the assay device are described.
Detailed descriptions of features of the assay, which minimize nonspeciﬁc binding and enhance the ability
to read results from weak-positive samples, are given. Basic principles used in assays with fundamentally
different reaction mechanisms, namely, antigen-detection, antibody-detection, and competitive assays are
given. Applications of ELISA technology, which led to the development of several multianalyte SNAP tests
capable of testing for up to 6 analytes using a single-sample and a single-SNAP device are described.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The enzyme-linked immunosorbent assay (ELISA) is one of the
most sensitive and speciﬁc diagnostic technologies available.
ELISA is the method of choice in reference laboratories worldwide
because of its unparalleled accuracy and ease of use. The SNAP
assay device contains reagents needed to conduct the steps
associated with the ELISA in-clinic with minimal hands-on time.
The SNAP assay was developed by scientists at IDEXX Laboratories
to overcome limitations of other clinic-based assays, which
included ﬁrst generation ELISA-, colloidal gold-, and latex par-
ticle–based tests. The SNAP product combines the simplicity and
immediate results of an in-ofﬁce test with the accuracy of a
reference laboratory-format ELISA.
The SNAP assay is by far the market leader in veterinary ofﬁce
diagnostics—approximately 19 million SNAP devices are run by
veterinarians each year.1,2 Since the introduction of the heart-
worm antigen SNAP assay in the early 1990s, the number of assays
using SNAP technology has expanded and currently includes over
20 different assays across a variety of assay formats for use in
widely different applications using diverse sample types (whole
blood, serum, plasma, feces, and milk). These include assays for
detection of antigens and antibodies typically associated with the
diagnosis of infectious diseases, the quantiﬁcation of metabolic
and cardiac hormone levels, and tests for antibiotic drug-residue
levels in milk. In-clinic SNAP assays designed for use as point-of-
care tests in veterinary clinics are described in this article.Features of the SNAP Assay
ELISA Format
The SNAP assay is an example of an ELISA. By convention,
ELISAs are immunoassays, which contain an enzyme-labeledicine. Published by Elsevier Inc. Tantibody or antigen (generally referred to as a conjugate) and
typically include an antigen- or antibody-binding step, a wash
step, and a color-generating step that involves enzymatic reaction
to produce a colored reaction product. Each of the basic steps in
the ELISA procedure has been incorporated in the SNAP assay. The
SNAP assay was developed to provide timed, automatic, and
sequential ﬂow of sample, conjugate, and wash, substrate reagents
in a simple easy-to-use device that can be run in clinic.1
Basic SNAP Assay Procedure
The SNAP assay device is shown in Fig 1. Procedurally, an
enzyme-labeled conjugate is mixed with serum, plasma, or whole
blood in a tube and added to the sample well of the SNAP device. The
sample-conjugate mixture ﬂows through the matrix, interacts with
test and control spots deposited on the matrix, and reaches the
activation circle in approximately 30-60 seconds. The device is then
activated (by depressing or “snapping” the activator), which results
in the release of wash buffer and substrate solution from reagent
reservoirs contained within the device. Positive results are visualized
by the formation of colored reaction products; the assay is complete
in 6-10 minutes depending on the test. The development of color in
the positive control indicates that the assay reagents are functional.1Detailed SNAP Assay Mechanism
The SNAP device architecture and its functional mechanisms
are shown in Fig 2. The basic steps in the ELISA procedure are fully
described.
Initial Antigen or Antibody Conjugate Reaction
The conjugate is an antibody or antigen covalently attached
to the enzyme horseradish peroxidase (HRPO). The conjugatehis is an open access article under the CC BY-NC-ND license
Fig. 1. The SNAP assay device.1
Fig
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application to the SNAP device (Fig 2.1). The conjugate reagent
reacts speciﬁcally with the target analyte in the sample (if present)
and forms an HRPO-labeled antigen-antibody complex.
Flow Matrix and Sample Flow
The ﬂow matrix is a brilliant white porous polyethylene
material, which is the centerpiece of the SNAP device. Operation-
ally, sample, conjugate reagent, wash buffer, and substrate sol-
ution all ﬂow through the polyethylene matrix. Immobilized
reagents are applied to the matrix in separate areas as test and
control spots in a pattern that allows reactions to occur independ-
ently in a reagent-speciﬁc fashion (Fig 2.2).
The sample-conjugate reagent mixture applied to the sample
well ﬂows through the matrix and reaches the test spots (Fig 2A).
HRPO-labeled antigen-antibody complexes (if present) bind to. 2. Detailed mechanism of the SNAP device. Reaction mechanism is shown for an antige
antibody-detection assay would be similar but would use immobilized antigen and anthe antigen or antibody reagents deposited in these spots to form
immune complexes (Fig 2.3).Device Activation and Bidirectional Flow
The SNAP device is manually activated (or automatically with a
SNAP Pro Mobile Device) when the ﬂow of the sample-conjugate
mixture reaches the activation circle. Activation of the SNAP
device initiates additional steps in the ELISA procedure as
described below:(1)n-det
antigSeparate wash buffer and substrate solution reservoirs are
punctured; wicks are forced into contact with the matrix and
direct the ﬂow of wash buffer and substrate solution to the
matrix.(2) The sample well end of the matrix is forced into contact with
an absorbent block that absorbs liquid and reverses the ﬂow of
liquid through the matrix.Activation of the SNAP device initiates the reverse ﬂow process
—the ﬂow of wash buffer (Fig 2B) and substrate solution (Fig 2C)
from the reagent reservoirs through the matrix to the absorbent
block in the opposite direction of the initial ﬂow of sample and
conjugate reagent.Wash Step
The wash buffer is a solution containing detergent, nonspeciﬁc
protein, and preservatives. The wash buffer removes unbound
debris and unreacted conjugate reagent from the matrix and
produces a clean, untarnished background so that results can be
easily interpreted (Fig 2.5).ection assay using immobilized antibody and an antibody-HRPO conjugate.
en-HRPO conjugate.
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The substrate solution used in the SNAP assay contains TMB
(3,3’, 5,5’-tetramethylbenzidine). This is a precipitating substrate
solution—upon reaction mediated by the enzyme HRPO, the
substrate turns distinct blue in color and becomes insoluble. This
signiﬁes and marks the location of positive results (Fig. 2.6).Advantages of Bidirectional Flow of Wash and Substrate
A schematic representation of the reverse ﬂow process show-
ing spot placement and reagent ﬂow is given in Fig 3. Sample-
conjugate reagent mixture is applied to one end of the ﬂow matrix
and ﬂows in the forward direction, whereas wash buffer and
substrate solution are applied to the opposite end (when the
device is activated) and ﬂow in the reverse direction. The ﬂow of
wash buffer and substrate solution in the reverse orientation is
very efﬁcient and has several advantages:(1)Fig.
sam
of thWash buffer interacts directly with the test spots in the read
window and does not pass through unreacted conjugate and
sample debris in the vicinity of the sample well; this reduces
the amount of unbound material that needs to be washed off
the matrix and minimizes background coloration.(2) The time needed to wash the matrix is reduced.
(3) The sample-conjugate reagent mixture is exposed to the solid
phase reagents in both forward and reverse directions, which
increases contact time and offers a second opportunity to bind
with the test spots.(4) The wash buffer and substrate solution are contained in
separate reservoirs and ﬂow through the matrix in a tandem
fashion. The wash buffer and substrate solution do not mix, a
frontal boundary forms between the reagents as they migrate
through the matrix—nonspeciﬁcally bound components and
unreacted conjugate reagent are removed by washing before
exposing the matrix to substrate. This reduces nonspeciﬁc
background and enhances the ability to read results.The wash step, and particularly its reverse ﬂow orientation, is a
key element of SNAP assay technology. Notwithstanding the
efﬁciency of the wash reagent itself, the reverse ﬂow orientation3. Schematic representation of the SNAP ﬂow matrix showing the ﬂow of the
ple-conjugate reagent in the forward direction and the reverse ﬂow orientation
e wash buffer and substrate solution.and the sequential ﬂow of wash and substrate are largely respon-
sible for the almost pristine white background observed in the
SNAP assay.Comparison of the SNAP Assay to Other In-Clinic Technologies
Several lateral-ﬂow immunoassays have been developed for use
in veterinary clinics that use colloidal gold or colored latex particles
attached to diagnostic reagents in place of the enzyme conjugates
used in ELISA. The accumulation of gold or colored latex particles on
the diagnostic test spot or line signiﬁes a positive result.
The SNAP ELISA has several advantages over the colloidal gold-
and latex particle–based lateral-ﬂow assays. As described previ-
ously, SNAP ELISA uses reverse directional ﬂow, a wash step to
eliminate nonspeciﬁc binding, an enzymatic reaction step to
amplify signal development, and a distinct blue-colored reaction
product that is easy to observe against the background of the
white-colored matrix. A practical example that illustrates the
advantages of the wash and enzyme reaction steps is found when
using hemolyzed samples. Results for hemolyzed samples can be
difﬁcult to interpret using colloidal gold-format assays because of
red background coloration on the ﬂow matrix, which makes it
difﬁcult to observe color development on the test line. In the SNAP
ELISA, there is little or no background color, and blue-colored
positive results are easily interpreted because of the high color
contrast between spot and sample color. Fig 4 shows results of a
colloidal gold-format assay and SNAP ELISA using a hemolyzed
weak heartworm antigen-positive sample. In this case, the result
is readily observable in the SNAP ELISA but very difﬁcult to detect
in the colloidal gold-format assay. Differences in the SNAP assay
and lateral-ﬂow assay are summarized in Table 1. Studies have
shown sensitivity limitations for several colloidal gold-format
lateral-ﬂow assays.3 The SNAP-format ELISA was shown to be
more sensitive than colloidal gold lateral-ﬂow assays for feline
leukemia virus antigen4 and detection of antibody to tick-borne
agents (Anaplasma spp., Ehrlichia spp., and Borrelia burgdorferi).5,6Diversity of SNAP Assay Applications
Antigen and Antibody-Detection Assays
Assays with fundamentally different reaction mechanisms, namely
antigen- and antibody-detection, can be performed using the SNAP
device. Antibodies and antigens can be immobilized on the matrix or
conjugated to HRPO. An antibody pair (immobilized antibody and
conjugated antibody) is used in antigen-detection assays and an
antigen pair (immobilized antigen and conjugated antigen) is used
in antibody-detection assays. Fig 5 is a representation of the immuneFig. 4. Assay devices obtained following testing of a hemolyzed known heartworm
antigen-positive sample using a commercially available colloidal gold-format
lateral-ﬂow assay (A) and the SNAP 4Dx Plus ELISA (B).
Table 1.
Comparison of SNAP Assay to Colloidal Gold Lateral-Flow Assay
Assay Step Colloidal Gold-Based Lateral-Flow Assays SNAP Assay
Wash step No wash step Wash step removes unbound sample components and unreacted
conjugate before addition of substrate.
Flow orientation Unidirectional ﬂow Bidirectional ﬂow of sample and wash or substrate provides a second
chance of binding and eliminates nonspeciﬁc color development.
Mechanism of signal generation Accumulation of gold particles Enzymatic signal ampliﬁcation
Color of result Read result may be difﬁcult to interpret
especially with whole blood samples
Distinct blue dot enhances ability to read result
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detection assays. These assays take place independently of each other
and can be carried out on the same SNAP assay device.
Multianalyte Combination Assays
Several SNAP-format combination assays have been developed,
which test for several analytes in a single-assay step. The reagents
used in these combination assays are highly optimized and are
analyte-speciﬁc—reagents used in one assay do not cross-react
with the other assays on the same device. One or more antigen- or
antibody-detection assay can be performed simultaneously using
the same assay device from a single-sample aliquot. This versa-
tility has led to a number of combination assays that are widely
used in veterinary medicine to test for several analytes simulta-
neously and have revolutionized in-ofﬁce diagnostic testing.
The wash step and bidirectional ﬂow of sample and reagents
are key features of the SNAP assay needed to produce clean
backgrounds in multianalyte assays. Traditional combination
assays require the use of multiple conjugates that increases the
conjugate load and can result in nonspeciﬁc coloration of the
matrix. This can make it difﬁcult to distinguish nonspeciﬁc back-
ground from color produced by analyte-speciﬁc reactions. In the
SNAP combination assays, sample debris and unreacted conjugate
are efﬁciently removed from the matrix, which results in a clean
white background so that false-positive results due to nonspeciﬁc
reactions are almost nonexistent and weak-positive results can be
easily detected.
The initial SNAP-format assay was a single-analyte assay for
heartworm (Diroﬁlaria immitis) antigen, which was introduced in
1992. Since that time, additional analytes have been added to the
original test in an incremental fashion—starting with the combi-
nation assay for heartworm antigen and Ehrlichia canis antibody
and leading to the SNAP 4Dx Plus test (2012) that added assays forFig. 5. Representation of the immune complexes formed on the SNAantibodies to 4 additional tick-borne agents. Fig 6 gives brief
details on the IDEXX SNAP point-of-care tests; additional infor-
mation is available on the IDEXX Website.7
Semiquantitative SNAP Assays
Several SNAP-format semiquantitative assays have been devel-
oped, which enable quantitative measurement of analyte levels in
patient’s samples. The assays contain a reference spot and a
sample spot, which binds antigen—results are determined by
comparing the intensity of color in the patient sample spot to
the reference spot. Relative color intensity can be assessed visually
or with an automated SNAP assay reader that electronically
measures and compares the optical differences of the 2 spots.8
Pancreatic Lipase SNAP Test
There are 2 semiquantitative SNAP-format assays (SNAP cPL
and SNAP fPL) that have been designed to provide a measure of
the immunoreactive pancreatic-speciﬁc lipase in canine and feline
serum samples. The tests use monoclonal antibodies that react
with different epitopes of the canine and feline pancreatic lipases
as conjugate and matrix reagents. The pancreatic lipase present in
the sample binds to the conjugate antibody and the capture
antibody. The SNAP result shows a blue-colored reaction product
that is proportional to the amount of pancreatic lipase in the
sample.9SNAP Feline proBNP Test
The SNAP Feline proBNP test provides a semiquantitative
measurement of the concentration of a breakdown product of
BNP (brain natriuetic peptide) referred to as NT-proBNP. The test
uses antibodies as conjugate and matrix reagents. The sample is
mixed with the antibody conjugate that binds NT-proBNP andP ﬂow matrix following antigen- and antibody-detection assays.
Fig. 6. IDEXX SNAP point-of-care tests.
T.P. O’Connor / Topics in Companion An Med 30 (2015) 132–138136then reacts with antibody immobilized on the matrix. Upon
completion of the SNAP assay, a blue-colored reaction product is
formed that is proportional to the concentration of NT-proBNP in
the sample.8SNAP Device Automation
IDEXX Laboratories has produced several instruments that aid
in running and recording SNAP assay results.
T.P. O’Connor / Topics in Companion An Med 30 (2015) 132–138 137SNAPshot Dx Analyzer
The SNAPshot Dx Analyzer (Fig 7) is an advanced optical
system that allows the user to load certain SNAP devices
immediately following the activation step. The analyzer quickly
and efﬁciently reads the SNAP test result at the appropriate
time, interprets SNAP test results consistently and accurately,
and integrates the results into the patient record and invoice.
The SNAPshot Dx Analyzer connects to the IDEXX VetLab
Station, which provides a comprehensive picture of the
patient’s health.
SNAP Pro Mobile Device
The SNAP Pro Mobile Device (Fig 8) automatically activates
the SNAP device at the appropriate time following sample
application, properly times the run and captures an image of
the ﬁnal SNAP result. The ﬁnal result can be stored electroni-
cally and displayed on the SNAP Pro Mobile screen. The SNAP
Pro Mobile Device connects wirelessly to the IDEXX VetLab
Station and ensures that all SNAP test results are recorded in
the patient record and entered into the customer record for
billing.Fig. 8. IDEXX SNAP Pro Mobile Device.SNAP Device Studies
The accuracy of SNAP-format assays has been commonly
accepted; the SNAP assay is the most frequently used in-clinic
diagnostic platform worldwide and has become the standard of
comparison for veterinary in-clinic assays.1 The results of a largeFig. 7. IDEXX SNAPshot Dx Analyzer.number of studies have been published to validate individual
SNAP assays and to report infection rates in small regional and
large national studies.
The following is a list of recent publications that describe the
use of SNAP assays: SNAP 4Dx Plus,10-13 SNAP 4Dx,14-16 SNAP
3Dx,17-19 SNAP Heartworm RT,20,21 SNAP Feline Triple,22 SNAP FIV/
FeLV Combo,23-25 SNAP FIV/FeLV Combo Plus,26 SNAP Parvo,27-29
SNAP Leishmania,30-32 SNAP Giardia,33 SNAP Lepto,34,35 SNAP cPL,9
SNAP fPL,9 and SNAP Feline Pro BNP,8.References
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